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Abstract Over the last decade our insight into the causes
of neonatal diabetes has greatly expanded. Neonatal
diabetes was once considered a variant of type 1 diabetes
that presented early in life. Recent advances in our
understanding of this disorder have established that
neonatal diabetes is not an autoimmune disease, but rather
is a monogenic form of diabetes resulting from mutations in
a number of different genes encoding proteins that play a
key role in the normal function of the pancreatic beta-cell.
Moreover, a correct genetic diagnosis can affect treatment
and clinical outcome. This is especially true for patients
with mutations in the genes KCNJ11 or ABCC8 that encode
the two protein subunits (Kir6.2 and SUR1, respectively) of
the ATP-sensitive potassium channel. These patients can be
treated with oral sulfonylurea drugs with better glycemic
control and quality of life. Recently, mutations in the
insulin gene (INS) itself have been identified as another
cause of neonatal diabetes. In this article, we review the
role of INS mutations in the pathophysiology of neonatal
diabetes.
Keywords ER stress.Insulin.Maturity-onset diabetes of
the young.Neonatal diabetes.Type 1 diabetes.Unfolded
protein response
1 Introduction
Insulin plays a key role in the regulation of glucose
homeostasis with diabetes resulting from insulin deficiency,
whether complete deficiency as in type 1 diabetes or relative
deficiency as in type 2 diabetes. A genetic basis for diabetesis
well established with some forms resulting from a mutation in
asinglegene(monogenicformsofdiabetes)andothersfroma
combination of common, and possibly rare, genetic variants
acting together with environmental factors to affect risk of
disease (polygenicforms ofdiabetes) [1]. Insulin was the first
protein to be completely sequenced [2] with the amino acid
sequence of bovine insulin determined by Sanger and his
colleagues from 1951–1955. The amino acid sequence of
human insulin was reported by Nicol et al. in 1960 and
human proinsulin (the single-chain precursor to insulin) by
Oyer et al. in 1971 [3–5]. The human preproinsulin cDNA
and complete amino acid sequence of preproinsulin were
identified by Bell et al. in 1979 and the cloning and the
characterization of the human insulin gene by Bell et al. in
1980 [6, 7].
Studies of human insulin from nondiabetic and diabetic
patients suggested that differences in sequence could be a
genetic cause of diabetes but definitive proof was lacking
(reviewed in Kimmel et al. 1967) [8]. The first mutant
human insulin protein was identified by Tager and
colleagues in 1979 and subsequently mutant proinsulin in
1981 in patients with hyperinsulinemia and hyperproinsu-
linemia, respectively, both very rare conditions with only
15 families reported to date [9–12]. Moreover, most
patients with hyperinsulinemia or hyperproinsulinemia did
not develop overt diabetes. These studies suggested that if
mutations in the human insulin gene were a cause of
diabetes, they were very rare and unlikely to be a
significant factor contributing to disease. This view has
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and others reporting the identification of many new mutations
in the insulin gene in humans and mice [13–19]. Mutations in
the human insulin gene (INS)a r eac o m m o nc a u s eo f
permanent neonatal diabetes mellitus (PNDM). They can
also result in diabetes diagnosed outside infancy with a
diagnosis of type 1b diabetes or maturity-onset diabetes of
the young. They are also the cause of diabetes in two mouse
models–the Akita and Munich mouse. Clinical studies of
these patients and molecular and cell biological studies of the
mutant insulin, preproinsulin and proinsulin proteins are
providing new insight into the pathophysiology of diabetes
as well as insulin biosynthesis [18, 19].
2 Molecular structure of insulin and insulin biosynthesis
Insulin is the major biosynthetic and secretory product of
the beta cell accounting for 20% of total mRNA (100–
200,000 insulin mRNA molecules/cell), 10% of total
cellular protein and 50% or more of total protein synthesis
when maximally stimulated corresponding to 1.3×10
6
molecules of insulin/min [20, 21].
The initial product of translation of human insulin mRNA
is a single chain precursor molecule, preproinsulin, a protein
of 110 amino acid residues including the signal peptide of 24
amino acid residues. The emerging signal peptide first
interacts with the signal recognition particle in the cytosol.
This complex then interacts with the translocon on the ER
membrane which targets the nascent proinsulin peptide chain
into the ER. The signal peptide is rapidly cleaved and
degraded and proinsulin then folds in the lumen of the ER
forming the characteristic disulfide bonds of the insulin
molecule. In proinsulin, the C-peptide bridges the B-chain
and the A-chain via two pairs of basic amino acids (Arg-Arg
and Lys-Arg, respectively) (Fig. 1). In mature insulin, the C-
peptide and the four basic residues have been excised and the
B- and A-chains are connected covalently only by the two
disulfide bonds between the B7-A7 and B19-A20 cysteines.
A third intrachain disulfide bond connects A6 and A11
cysteines. The folding of proinsulin and disulfide bond
formation are catalyzed by several classes of ER chaperone
proteins. Only the fully folded native proinsulin protein can
normally progress from the ER to the Golgi compartments.
After transitioning through the Golgi apparatus, the proinsu-
lin is concentrated and sorted into immature secretory
granules in the transGolgi network. The proteolytic process-
ing of proinsulin to insulin and C-peptide takes place mainly
in the maturing secretory granules by cleavage sequentially
at the B-chain-C-peptide junction by proconvertase (PC) 1/3
and carboxypeptidase E (CPE) yielding des-31,32-proinsulin
and then at the C-peptide-A-chain junction by PC2 and CPE
yielding insulin and C-peptide. Three molecules of Arg and
one molecule of Lys are released during this process. Insulin
and C-peptide are stored in the mature secretory granules and
secreted in equimolar amounts [22].
3 Insulin mutations in monogenic forms of diabetes
3.1 Insulin mutations and diabetes
Insulin gene mutations as a cause of diabetes were identified
independentlybyourselves(Støyetal.2007)andbyColombo
et al. (2008) [13, 17]. We carried out a linkage analysis in a
three-generation family with PNDM of unknown etiology.
The results suggested that the putative diabetes gene was
located on either chromosome 2, 3, 6 or 11. Cataloguing the
genes under the linkage peaks of each of these chromosomes
revealed two candidate genes—NEUROD1 and INS. There
were no mutations in the coding region of NEUROD1.
Sequencing of INS revealed the missense mutation G32S in
affected family members suggesting that an INS mutation
was responsible for PNDM in this family. The association of
INS mutations with PNDM was confirmed by the identifi-
cation of mutations in 15 additional probands. Interestingly,
the majority of the mutations were not inherited but were de
novo in origin. All were in the heterozygous state. Colombo
et al. [17] used a candidate gene approach based on the fact
that a mutation in the Ins2 gene (the mouse homolog of the
insulin gene in human) was the cause of diabetes (described
as maturity-onset diabetes of the young) in the Akita mouse
model of diabetes [18]. They identified seven different INS
mutations in 9 probands with PNDM.
Mutations (in the heterozygous state) in INS have now
been reported in 66 probands with a variety of diagnoses
including PNDM, infancy-onset diabetes (i.e. diabetes
diagnosed before 12 months of age), type 1b diabetes
(i.e. non-autoimmune type 1 diabetes (T1DM)), maturity-
onset diabetes of the young (MODY), and early-onset type 2
diabetes (T2DM) (Figs. 1–2 and Table 1)[ 13–17, 23–28].
There are multiple affected family members in 23/66
families. Of the 107 carriers in these families, 104 have
diabetes and three have normal glucose tolerance.
In the large Exeter cohort of patients with PNDM
diagnosed before 6 months of age, 14% of patients born
to non-consanguineous parents were found to carry a
heterozygous INS mutation. The incidence of INS mutations
in patients diagnosed with diabetes outside the neonatal
period is less well defined, but is estimated to be less than
2%. The mutations in 18/66 (27%) of the probands were
inherited from an affected parent whereas in the remaining
48 probands (73%) the mutation was de novo in origin. In
one family, two affected children with the same mutation
were born to unaffected parents, neither of them carriers,
suggesting that one of the parents was a germline mosaic.
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structurally abnormal preproinsulin or proinsulin protein. The
mutations are locatedinthe signalpeptide,theB-chainandA-
chain regions and the pairs of basic residues that flank the C-
peptide. Those located in the signal peptide impair the
function of this domain of preproinsulin including absent or
altered cleavage of the signal peptide. The mutations in
proinsulin affect formation of the disulfide bonds linking the
B-chain and A-chain as well as the intra-A-chain disulfide
bond thereby leading to a misfolded proinsulin molecule that
is retained in the ER impairing normal beta-cell function and
resulting in cell death [17, 19, 29–31].
Garin et al. [32] recently reported recessive mutations in
INS resulting in neonatal diabetes. These mutations affect
proinsulin biosynthesis per se and function as null
mutations, doing so by several different mechanisms. One
mutation results in deletion of exons 1 and 2 of the insulin
gene. There are several mutations located in the promoter
region of the gene that result in decreased transcription.
A mutation in the region encoding the 3′-untranslated
region of the mRNA affects polyadenylation and mRNA
stability. Other mutations affect translation of insulin
mRNA by mutation of the translation initiation codon, or
lead to synthesis of a truncated proinsulin molecule
(Figs. 1 and 3).
Homozygous mutations in INS have been reported in 15
families/21 patients. These patients were diagnosed with
PNDM (67% of patients), type 1b diabetes (9% of patients)
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Fig. 1 Diagrammatic representation of the amino acid sequence of
human preproinsulin (signal peptide–green, B-chain–red, C-peptide–
orange, A-chain–dark blue) indicating sites of mutations identified in
patients with diabetes as well as hyperinsulinemia and hyperproinsuline-
mia. Mutationsshown inblack disrupt proinsulin foldingand/or disulfide
bondformationleadingtopermanentneonataldiabetesmellitus(PNDM);
mutations in light blue do not impair folding but are associated with
reduced insulin receptor binding potency (hyperinsulinaemia); mutations
in light green are associated with hyperproinsulinaemia and either impair
proteolytic processing to insulin or, in the case of H34D, aggregation and
sorting into dense-core granules of the regulated secretory pathway.
Mutations in pink and purple were found in patients with a diagnosis of
maturity-onset diabetes of the young (MODY) and type 1b diabetes,
respectively. The R55C mutation has been found in patients with a
diagnosis of type 1b diabetes as well as MODY. The mutations shown
in gray (A23S, A23T, L68M and G84R) are rare variants without
functional effects on proinsulin/insulin biosynthesis. The mutations
shown in yellow are recessive mutations that affect insulin biosynthesis
(mutation of the translation initiation Met) or cause the synthesis of a
nonsense protein (Q62X)
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transient neonatal diabetes mellitus (TNDM) (24% of
patients). Homozygous INS mutations are the most com-
mon cause of PNDM without extra-pancreatic features in
patients born to consanguineous parents (~32%), but are a
rare cause of neonatal diabetes in patients born to non-
consanguineous parents (~1%) [32].
3.2 Characteristics of mutations
All the mutations in the preproinsulin protein reported to
date are shown in Fig. 1. In addition to the mutations
associated with diabetes, hyperinsulinemia or hyperproin-
sulinemia, there are four mutations that are unlikely to be
pathogenic: A23S, A23T, L68M and G84R [14, 23, 28]
(Figs. 1 and 2). The mutation A23S has been reported to be
associated with type 1b diabetes. However, this site is not
highly conserved amongst preproinsulin sequences and is
Ser in the chimpanzee sequence strongly suggesting that it
does not lead to diabetes (Fig. 4). Functional studies
indicate that G84R does not affect proinsulin biosynthesis
suggesting that the putative diabetes-associated mutation is
not pathogenic [30].
The dominantly-acting diabetes-associated mutations
involve 19/110 amino acids of preproinsulin and include
23 missense mutation, one nonsense mutation and one
insertion/deletion mutation. They are located in all regions
of the preproinsulin molecule except the C-peptide: signal
peptide (3 mutations), B-chain (12 mutations), A-chain
(8 mutations) and pairs of basic amino acids that flank the
C-peptide (2 mutations). The latter mutations are found at
the enzymatic cleavage site between the B-chain and
C-peptide (R55C) and the C-peptide and A-chain (R89C).
Other mutations of Arg89 have been described in patients
with hyperproinsulinemia. Thirteen mutations were identi-
fied in more than one proband (Fig. 2, Table 1) and
mutations at five codons (A24D, G32S/R, F48C, R89C,
and C96Y/S) account for 56% (37/66) of all mutations
identified to date. Six residues are sites for different amino
acid substitutions: R6C/H, A23S/T, L30M/P/V, G32S/R,
C96Y/S and Y108C/X. Five mutations were identified in
families where all affected family members were diagnosed
with diabetes outside the neonatal period or infancy (R6C,
R6H, L30M, R46Q and R55C) highlighting the different
effects of these various mutations on pancreatic beta-cell
function. As noted above, A23S/T, L68M, and G84R are
most likely rare variants that are not pathogenic and
patients carrying these variant are not included in the
genotype/phenotype analyses described below.
Ten different homozygous INS mutations have been
reported to date [32]. Five homozygous mutations have
been found in regions of INS affecting transcription or
INS mutations
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Fig. 2 Summary of human insulin gene mutations and disease
phenotype. The numbers in brackets indicate the number of probands
with that specific mutation. PNDM, permanent neonatal diabetes
mellitus; TNDM, transient neonatal diabetes mellitus; MODY,
maturity-onset diabetes of the young; T1BDM, type 1b diabetes
mellitus
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Location of mutation Mutation Homozygous/
Heterozygous
Probands/
Patients
Phenotype/Diagnosis
(Number of subjects)
Reference
Protein change Nucleotide
change
Promoter, signal peptide,
B-chain, C-peptide
– c.−370-?_186+
?del
Homozygous 1/2 PNDM [32]
Promoter – c.−366_−343del Homozygous 1/2 PNDM [32]
Promoter – c.−331 C>A Homozygous 2/2 TNDM [32]
Promoter – c.−331 C>G Homozygous 5/9 PNDM (6), TNDM (1),
T1BDM (2)
[32]
Promoter – c.−332 C>G+c.
−331 C>G
Compound
heterozygous
1/1 TNDM [32]
Promoter – c.−218 A>C Homozygous 1/1 TNDM [32]
Signal peptide p.0? (M1I) c.3 G>T Homozygous 1/1 PNDM [32]
Signal peptide p.0? (M1I) c.3 G>A Homozygous 1/1 PNDM [32]
Signal peptide R6C c.16 C>T Heterozygous 1/3 MODY [14]
Signal peptide R6H c.17 G>A Heterozygous 1/4 MODY/ T2DM / GDM /
Normal
[26]
Signal peptide A23S c.67 G>T Heterozygous 1/1 T1BDM* [23]
Signal peptide A23T c.67 G>A Heterozygous 1/4 T2DM (2) / IGT (1) /
Normal*
[28]
Signal peptide A24D c.71 C>A Heterozygous 6/8 PNDM (7) / T1BDM (1) [13, 14, 16]
B-chain H29D c.85 C>G Heterozygous 1/1 PNDM [14]
B-chain L30V c.88 C>G Heterozygous 1/1 PNDM [17]
B-chain L30M c.88 C>A Heterozygous 1/6 MODY (5) / Normal [26]
B-chain L30P c.89 T>C Heterozygous 1/1 PNDM [17]
B-chain G32S c.94 G>A Heterozygous 5/8 PNDM (7) / T1BDM (1) [13, 14, 23, 24]
B-chain G32R c.94 G>C Heterozygous 2/5 PNDM (4) / MODY (1) [13, 14]
B-chain L35P c.104 T>C Heterozygous 2/2 PNDM [14, 17]
B-chain L39_Y40delinsH c.114_118
TCTCT>AC
Heterozygous 1/1 PNDM [17]
B-chain C43G c.127 T>G Heterozygous 2/3 PNDM (2) / T2DM (1) [13, 14]
B-chain R46Q c.137 G>A Heterozygous 2/6 MODY [15, 27]
B-chain G47V c.140 G>T Heterozygous 2/2 PNDM [13, 14]
B-chain F48C c.143 T>G Heterozygous 5/6 PNDM [13, 14]
C-peptide/B-chain
junction
R55C c.163 C>T Heterozygous 2/5 T1BDM (2) / MODY (3) [15, 26]
C-peptide Q62X c.184 C>T Homozygous 1/1 PNDM [32]
C-peptide L68M c.202 C>A Heterozygous 1/1 T2DM* [14]
C-peptide G84R c.250 G>A Heterozygous 1/1 PNDM* [14]
C-peptide/ A-chain
junction
R89C c.265 C>T Heterozygous 13/20 PNDM (15) / T1BDM (5) [13, 14, 16, 17, 24]
A-chain G90C c.268 G>T Heterozygous 2/2 PNDM [13, 14]
A-chain C95Y c.284 G>A Heterozygous 1/1 PNDM [17]
A-chain C96Y c.287 G>A Heterozygous 5/7 PNDM (6) / T1BDM (1) [14, 16, 25]
A-chain C96S c.287 G>C Heterozygous 1/1 PNDM [14]
A-chain S101C c.302 C>G Heterozygous 2/3 PNDM [14]
A-chain Y103C c.308 A>G Heterozygous 1/1 PNDM [14]
A-chain Y108C c.323 A>G Heterozygous 1/2 PNDM [14]
A-chain Y108X c.324 C>G Heterozygous 1/1 PNDM [17]
3′ UTR – c.59 A>G Homozygous 1/1 PNDM [32]
Mutations associated with hyperinsulinemia and hyperproinsulinemia are not included in this table
*Uncertain pathogenicity. TIBDM, type 1b diabetes mellitus; T2DM, type 2 diabetes mellitus; GDM, gestational diabetes mellitus; IGT, impaired
glucose tolerance; 3′ UTR, 3′-untranslated region
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24-base pair deletion are located in the promoter and
one single base substitution is in the 3´-untranslated region
(3′-UTR). One patient was a compound heterozygote for two
promoter mutations. Four homozygous mutations have been
identified that affect the coding regions of INS: two different
mutations that result in mutation of the translational initiation
site (M1I), a large deletion of exons 1 and 2 (M1_Q62del)
and a nonsense mutation in the C-peptide region (Q62X).
The site in the promoter at c.-331 seems to be a mutational
hotspot, with seven probands identified with mutations at
this site (c.-331C>G and c.-331C>A).
3.3 Clinical characteristics of patients with PNDM
due to heterozygous (dominant-negative) insulin mutations
The majority of patients with heterozygous mutations in
INS were diagnosed with diabetes before 6 months of age
(85% in the Exeter cohort). However, in contrast to the
majority of patients with mutations in KCNJ11 or ABCC8,
INS mutations have also been found in patients diagnosed
from 6–12 months of age. Ninety-six percent of patients
with a heterozygous INS mutation in the Exeter cohort were
diagnosed with diabetes in the first year of life. The age-at-
diagnosis of diabetes (excluding patients with the mutations
R6C/H, L30M, R46Q and R55C) varies from 0–1,560 weeks
with a median of 11 weeks in the Exeter cohort and 26 weeks
intheremainingpatients.IncontrasttotheAkitamousewhere
there appears to be a difference in age-at-onset of diabetes
between male and female mice (with males having an earlier
onset with more severe hyperglycemia, at least on a C57BL/6
background) [18], there is no difference in age-at-diagnosis
between male and female human carriers of a heterozygous
INS gene mutation. Both male and female human carriers
present with severe beta-cell failure at diagnosis including, in
some instances, diabetic ketoacidosis or severe symptomatic
Exon 1 Exon 2 (a.a. 1-62) Exon 3 (a.a. 63-110)
c.3G>T(p.0?)
c.3G>A(p.0?) c.184C>T(p.Q62X)
c.*59A>G
c.-218A>C
c.-331C>G
c.-331C>A
c.-332C>G+ c.-331C>G
c.-370-?_186+?del
c.-366_-343del
5’ 3’
Fig. 3 A schematic of the human insulin gene showing the locations
of mutations in the homozygous or compound heterozygous state in
probands with PNDM and TNDM. Mutations involving coding
regions are shown above the gene while those involving non-coding
regionsareshownbelowthegene.Theproteincodingregionsofthegene
are shown in gray and the regions encoding the 5′-a n d3 ′-untranslated
regions of insulin mRNA in yellow. The red and black text indicates
mutations identified in probands with TNDM and PNDM, respectively.
Exon 2 encodes amino acids (a.a.) 1–62 and exon 3 encodes amino acids
63–110 of the preproinsulin molecule. Adapted from Garin et al. [32]
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Fig. 4 Multiple sequence alignment of preproinsulin from fish to
human. The ClustalW2 alignment was obtained using the online
interface at EBI (http://www.ebi.ac.uk/Tools/clustalw2/index.html).
The sequence of the signal peptide is shown in green letters, the B-
chain in red, the C-peptide in orange and A-chain in blue. The basic
amino acids that flank the C-peptide and are the sites of proteolytic
processing are shown in black letters. The conserved Cys residues are
highlighted in yellow. Asterisks (*) indicate identical amino acids in
all the sequences shown in this alignment, colons (:) indicate
conserved residues and periods (.) indicate semi-conserved amino
acids. Note that these do not represent all the known preproinsulin
sequences but rather are a selection of representative sequences
210 Rev Endocr Metab Disord (2010) 11:205–215hyperglycemia, a sign of almost complete insulin deficiency.
The majority of patients are treated with insulin in full
replacement doses [14].
Mutation carriers are born small for gestational age with
median birth weights from 2,700–3,087 g (6th to 27th
percentile) most likely reflecting in utero insulin deficiency.
Interestingly, male carriers have been reported to have more
severe growth retardation than female carriers [14].
More than half of patients with diabetes due to a
heterozygous INS mutation have been screened for the
presence of beta-cell auto-antibodies (anti-GAD65, islet
cell antibodies (ICA) and insulin antibodies). There were
no detectable auto-antibodies except for anti-insulin anti-
bodies in some patients, most likely secondary to long-
standing insulin therapy. The majority of patients had no
residual beta-cell function as evidenced by low or
undetectable basal or stimulated C-peptide levels. These
measurements were in most cases performed months or
years after the diagnosis of diabetes. However in one
study, the C-peptide levels were determined at onset of
diabetes and in most patients at one or two other times.
These data suggest a gradual and progressive decline in
beta-cell function over time. Six of 11 patients had
normal, and in some instances, high C-peptide level at
diagnosis of diabetes, declining levels at the repeat
measurements and finally undetectable C-peptide months
or years after the onset of diabetes [17].
Neurological dysfunction is a key feature of the
phenotype of some patients with PNDM due to mutations
in KCNJ11 or ABCC8 [33–35]. Patients with INS mutations
do not have other associated extra-pancreatic features.
Some patients have complications secondary to longstand-
ing diabetes such as neuropathy and retinopathy. Signs of
insulin resistance (e.g. the presence of acanthosis nigricans)
have been noted in some overweight patients [13].
3.4 Clinical characteristics of patients with MODY
A subgroup of INS mutations is found exclusively in
patients diagnosed with diabetes outside infancy and early
childhood: R6H, R6C, L30M, R46Q and R55C. These
patients fulfill traditional MODY criteria: non-obese,
diagnosis generally <25 years of age and a family history
of diabetes consistent with autosomal dominant inheritance.
The diabetes is non-ketotic and the patients are treated with
diet, oral hypoglycemic agents (OHA) or insulin. The
majority of patients have residual beta-cell function as
evidenced by detectable C-peptide levels. The extent of
beta-cell failure could also be progressive, as some patients
have declining C-peptide levels over time. One exception to
the generally mild phenotype of this group of patients is a
Norwegian family with the R55C mutation. The proband
and her mother were diagnosed with diabetes under the
dramatic setting of diabetic ketoacidosis and they now both
require insulin in full replacement doses. A French family
with the same mutation has mild, non-ketotic diabetes. This
variation is presumably due to differences in genetic
background and its effect on diabetes phenotype. Carriers
of the R6H, R6C, L30M, R46Q and R55C mutations
appear to have a normal birth weight (median, 4,000 g).
However, birth weight in this group may be influenced by
the presence of diabetes in the mothers and more studies are
required to clarify the effect of these mutations on birth
weight [14, 15, 26, 27].
The relationship between genotype (i.e. specific INS
mutation) and phenotype is beginning to emerge from the
studies to date. Some mutations (R6C/H, L30M, R46Q and
R55C) are associated with a later age-at-diagnosis and a
milder clinical course with patients maintaining adequate
glycemic control on diet or oral hypoglycemic agents alone.
However, the majority of INS mutations results in diabetes
in the neonatal period and requires treatment with replace-
ment doses of insulin. There can be, however, differences in
the age-at-diagnosis of diabetes between carriers with the
same mutation even within the same family indicating the
role of other factors (genetic and nongenetic) in modifying
the effect of the mutant protein on beta-cell function.
3.5 Clinical characteristics of patients with neonatal
diabetes due to homozygous or compound heterozygous
mutations
The phenotype of patients with diabetes due to a homozygous
(or compound heterozygous) mutation in INS is characterized
by severe intrauterine growth retardation (birth weight,
<1 percentile) and diabetes most likely reflecting severe
insulin deficiency in the pre- and postnatal life, respectively.
The majority of patients are diagnosed with diabetes in the
first days or weeks of life. Again, there are no extra-
pancreatic manifestations.
The diabetes in this group of patients can be permanent
or transient. The patients with PNDM appear to have lower
birth weights (median SD scores for birth weight −3.9 vs.
−1.8, P=0.03) and diabetes diagnosed earlier in life (2 days
vs. 24 days, P=0.04) when compared to patients with
TNDM. The mutations c. −366_−343del, c.3G>A (p.0?),
c.3G>T (p.0?), c.184C>T (p.Q62X), c.−370−?186+?del)
and c.*59A>G) appear to be associated with PNDM
whereas the mutations at c.−218 and c.−331 have been
identified in patients with both PNDM (n=6) and TNDM
(n=5) as well as type 1b diabetes (n=2).
Interestingly, the carrier parents (i.e. heterozygous for the
mutation) of patients who are homozygous or compound
heterozygous for an INS mutation have normal glucose
tolerance indicating that a single insulin allele is sufficient to
provide the insulin required to maintain normal glycemia.
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Two mouse models of diabetes due to dominantly-acting
heterozygous insulin gene mutations have been described, the
Akita (Ins2
C96Y)a n dt h eM u n i c h( Ins2
C95S)m o u s e[ 18, 19].
The C96Y mutation has also been reported in humans. The
mutation C95S has not yet been described suggesting
additional human mutations will be found. Hyperglycemia
and hypoinsulinemia develop from the fourth week of life.
Male mice have a more severe phenotype with pronounced
polydipsia, polyuria, growth retardation and high mortality
rates. By contrast, female mice have only mild hyperglyce-
mia and normal life expectancy. This sexual dimorphism
remains unexplained, but could be related to protective
effects of estrogen.
Akita mice have reduced numbers of beta cells and
reduced pancreatic insulin content. There is no evidence of
inflammation of the islets as seen in islets from patients
with type 1 diabetes. Electron microscopic studies of beta
cells from diabetic Akita mice reveal severe organelle
dysfunction with enlarged ER, swollen mitochondria,
prominent lysosomes and a reduced number of secretory
granules. These findings are consistent with a block in the
progression of mutant proinsulin (and possibly some
normal proinsulin) from the ER to the Golgi apparatus
accompanied by ER stress. The accumulation of misfolded
mutant proinsulin in the ER leads to activation of the
unfolded protein response (UPR) including expression of
the pro-apoptotic CHOP gene. In this regard, the develop-
ment of diabetes is delayed by 8–10 weeks in Akita mice
lacking CHOP highlighting the role of the UPR and
apoptosis in beta-cell death in this model. Further studies
of the Akita and Munich mouse models could lead to a
better understanding of the pathophysiology of diabetes due
to expression of a mutant proinsulin protein and perhaps
novel approaches for treating this form of diabetes [31, 36].
5 Pathophysiology of insulin mutations
5.1 Structure/function studies of insulin mutations
Studies of the effects of mutations that affect processing of
preproinsulin to proinsulin or lead to misfolding of
proinsulin have shown that the mutant proteins accumulate
in the ER and are poorly secreted (Fig. 5). The expression
ER  C-peptide   Merge  Golgi 
WT 
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Fig. 5 Subcellular localization of wild-type (WT) and mutant human
proinsulin expressed in rat INS-1 insulinoma cells [30]. The location of
human C-peptide immunoreactive protein is shown in green, ER is shown
in red and the Golgi marker in cyan. Nuclei were stained with DAPI
(blue). The WT and R89H hyperproinsulinemia mutant proinsulins are
localized to secretory granules. By contrast, the C96Y PNDM-associated
mutant proinsulin is localized to the expanded ER and is not transported
from the ER to the Golgi and packaged into secretory granules
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and in time apoptosis. The mutant proteins also appear to
exert a dominant-negative effect on the synthesis and
secretion of native proinsulin due to induction of the UPR
and consequent attenuation of translation [17, 29, 30].
Hodish et al. (2010) have established an elegant
transgenic model to study the effect of the C96Y mutation
on insulin biosynthesis in vivo by crossing transgenic mice
expressing GFP-tagged proinsulin with Akita mice. They
show that the mutant (C96Y) proinsulin blocks native
proinsulin biosynthesis followed by loss of pancreatic beta-
cells. Thus, the aggregation of both mutant and native
proinsulin in the ER likely triggers ER stress [37].
5.2 Pathophysiology of homozygous insulin gene mutations
In contrast to the dominantly-acting mutations, the mutations
found in the homozygous state result in diabetes through
reduced insulin biosynthesis per se. These mutations affect
insulin biosynthesis by distinct mechanisms including gene
deletion, mutation of the translation initiation site, synthesis
of a nonsense protein, impaired transcription due to
mutations of critical transcription factor binding sites in the
promoter, and impaired mRNA polyadenylation leading to
insulin mRNA instability, all resulting in severely impaired
insulin production, but without ER stress. These patients
presumably have otherwise normal beta cells and the
transient nature of the diabetes in some of these patients is
consistent with this view [32].
6 Insulin gene mutations and familial syndromes
of hyperproinsulinemia and hyperinsulinemia with mild
diabetes
A subgroup of mutations in INS causes mild diabetes or
impaired glucose tolerance by another mechanism. These
mutations lead to the synthesis of an insulin with reduced
biological activity or prevent processing of proinsulin to
insulin leading to hyperinsulinemia or hyperproinsulinemia,
respectively. In contrast to the INS mutations associated with
PNDM, the beta cells are able to synthesize and secrete these
molecules, thus indicating that these variants of INS do not
per se lead to cellular or organelle dysfunction.
6.1 Hyperinsulinemia
Three rare missense mutations, F48S (insulin Los Angeles),
F49L (insulin Chicago), and V93L (insulin Wakayama)
(Figs. 1 and 2) have been identified in patients with
phenotypes ranging from normal glycemia to mild diabetes
and concomitant hyperinsulinemia [9, 38–43]. These
mutations affect amino acids involved in insulin receptor
binding (B24-Phe, B25-Phe and A3-Val) and as a conse-
quence the mutant insulins have reduced insulin receptor
affinity and biological activity. Mutation carriers have
hyperinsulinemia, but impaired glucose tolerance or overt
diabetes only develops in adults with insulin resistance.
When diabetes develops, it is mild and satisfactory
glycemic control can be achieved with diet, oral hypogly-
cemic agents or small doses of insulin.
6.2 Hyperproinsulinemia
Four rare heterozygous missense mutations in INS have been
identified in patients with a disorder characterized by hyper-
proinsulinemia and a variable degree of glucose intolerance:
three mutant forms of proinsulin that involve the C-peptide-
A chain junction (R89H (proinsulin Tokyo), R89L (proin-
sulin Kyoto) and R89P) and a mutation in the B-chain,
H34D (proinsulin Providence) [9–12, 44–49]. The glucose
intolerance varies from normal glucose tolerance to mild
diabetes that can in most cases be managed with diet only.
The substitution of Arg-89 for His, Leu or Pro at the
C-peptide-A-chainjunction(thesiteofproteolyticcleavageof
des-31, 32 proinsulin to insulin and C-peptide) interferes with
the action of the prohormone convertase PC2 and as a
consequence, these patients have high levels in the circulating
of a proinsulin-like material that has been cleaved only at the
B-chain-C-peptide junction. The INS mutation H34D causes
hyperproinsulinemia by another mechanism. A proportion of
newly synthesized Asp-B10 proinsulin is secreted unpro-
cessed in a glucose-independent manner via an unregulated
pathway and enters the circulation as Asp-B10 proinsulin
whereas the majority enters the regulated secretory pathway
and is processed and secreted as Asp-B10 insulin. The
reason for the missorting of Asp-B10 proinsulin is unclear
but might be related to the higher biological potency of both
Asp-B10 proinsulin and insulin relative to native proinsulin
and insulin which increases its binding to recycling insulin
receptors in the beta cell leading to its uncontrolled release
and/or lysosomal degradation [50]. Perhaps, Asp-B10
proinsulin, thus, reduces the requirement for release of
normally processed insulin (including Asp-B10 insulin) by
the regulated pathway.
7 Conclusion
Mutations in the insulin gene are associated with diverse
phenotypes from hyperinsulinemia and hyperproinsulinemia
to neonatal diabetes. These mutations (in both the heterozy-
gous and homozygous state) are a common cause of neonatal
diabetes. They can also be found in patients with a diagnosis
of type 1b diabetes or MODY. A correct genetic diagnosis in
these patients is important for correct classification of their
Rev Endocr Metab Disord (2010) 11:205–215 213disease as well as for purposes of genetic counseling.
Currently, there is no specific treatment for these patients
apart from insulin-based regimens when this is required but
future research may identify approaches for addressing the
cellular stress resulting from the biosynthesis of a mutant
proteinandtherebypreservingbeta-cellfunctionandallowing
the normal allele to provide the insulin necessary for
maintaining normal glucose tolerance.
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